Citigroup Begins Coverage on Celldex Therapeutics (NASDAQ:CLDX)

Citigroup initiated coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report report published on Monday, MarketBeat.com reports. The firm issued a buy rating and a $70.00 price target on the biopharmaceutical company’s stock.

CLDX has been the topic of a number of other reports. HC Wainwright reiterated a buy rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Thursday, September 26th. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a buy rating and a $58.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They issued a neutral rating and a $45.00 price objective on the stock. Cantor Fitzgerald restated an overweight rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Finally, Wells Fargo & Company upgraded shares of Celldex Therapeutics from a hold rating to a strong-buy rating in a report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics presently has an average rating of Moderate Buy and a consensus target price of $62.25.

Celldex Therapeutics Trading Down 1.4 %

Shares of CLDX stock opened at $29.68 on Monday. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The firm’s 50 day moving average is $36.90 and its 200-day moving average is $37.68.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The company had revenue of $2.50 million for the quarter, compared to analyst estimates of $1.13 million. Equities research analysts anticipate that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently bought and sold shares of the company. Handelsbanken Fonder AB increased its stake in Celldex Therapeutics by 23.2% in the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after purchasing an additional 2,600 shares in the last quarter. Mirador Capital Partners LP increased its position in shares of Celldex Therapeutics by 3.4% during the third quarter. Mirador Capital Partners LP now owns 116,147 shares of the biopharmaceutical company’s stock worth $3,948,000 after acquiring an additional 3,768 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Celldex Therapeutics by 124.6% during the third quarter. SG Americas Securities LLC now owns 20,316 shares of the biopharmaceutical company’s stock worth $691,000 after acquiring an additional 11,272 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Celldex Therapeutics during the second quarter worth $76,000. Finally, Teachers Retirement System of The State of Kentucky increased its position in shares of Celldex Therapeutics by 32.0% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 40,558 shares of the biopharmaceutical company’s stock worth $1,501,000 after acquiring an additional 9,829 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.